Silence Therapeutics plc
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
13. Other assets
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| $000s | $000s | |
| Prepayments | 8,930 | 13,124 |
| VAT receivable | 2,607 | 1,540 |
| Total other current assets | 11,537 | 14,664 |
| Deposits for properties | - | 356 |
| Prepayments | 127 | 3,234 |
| Other long-term assets | 127 | 3,590 |
At December 31, 2025 and 2024, the largest component of prepayments are prepaid third party costs for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies which fluctuate based on timing of payments and related expense.
Included within prepayments at December 31, 2025 and 2024 is $6.8 million and $11.0 million respectively, are expenditures relating to contracted research and development costs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.